头孢丙烯在下呼吸道细菌感染患者的药代动力学研究

The Pharmacokinetics Study of Cefprozil in Patients with Low Respiratory Tract Bacterial Infections

目的 通过研究下呼吸道细菌感染患者的头孢丙烯临床药代动力学参数,为临床选择合理给药方案提供依据.方法 用HPLC法测定10例下呼吸道细菌感染患者连续给药5 d后的稳态血药浓度,数据用3P97药物动力学模拟系统处理.结果 头孢丙烯的药-时曲线符合二室开放模型,主要药代动力学参数;t1/2为1.55±0.17h,MRT为2.52±0.15h,Cmax为13.32±1.28μg·mL-1,tmax为1.41±0.31h,AUC0～10为31.68±7.68μg/（h·mL^-1）.结论 口服头孢丙烯片500mg,每天2次,能获得控制下呼吸道细菌感染的有效治疗浓度.

OBJECTIVE The pharmacokinetic parameters of cefprozil in 10 patients with low respiratory tract bacterial infections were evaluated after multiple-dose of 500mg. METHODS The cefprozil concentration in plasma was determined by a high performance liquid chromatography method. Pharmacokinetic parameters were obtained by using 3P97 imitate program. RESULTS With oral multiple-dose of 500mg of cefprozil twice over 5 consecutive days,The main pharmacokinetic paramerters obtained from the patients were as follows：t1/z were 1.55±0. 17 h,MRT were 2.52±0. 15h,Cmax were 13.32±1.28μg·mL^-1,tmax were 1.41±0.31h,AUC0-10 were 31.68± 7.68μg/（h·mL^-1）. CONCLUSION respiratory tract bacterial infections. Cefprozil 500 mg,bid orally may be effective against low